



Borders Formulary Committee

Annual Report

April 2019 – March 2020

CONTENTS

1	NHS Borders Formulary Committee Purpose	Page 3
2	BFC Membership	Page 3
3	Business	Page 3
4	BFC – Formulary Updates	Page 4
5	BFC – Applications and Decisions	Page 5-7
6	BFC Meeting Attendees 2019/20	Page 7

1. Purpose

Borders Formulary Committee is a sub committee of the Area Drug and Therapeutics Committee and is accountable to the Strategy Group.

Its purpose is to provide NHS Borders Board with the assurance that mechanisms are in place and effective across NHS Borders to manage requests to support cost-effective, evidence based, prescribing of medicines.

2. BFC Membership

During the financial year ending 31 March 2020, membership of NHS Borders Formulary Committee comprised:

Mrs Alison Wilson (Chair) – Director of Pharmacy

Ms Liz Leitch – Formulary Pharmacist

Mrs Catherine Scott – Senior Clinical and Development Pharmacist

Mrs Cathryn Park - Lead Pharmacist Acute Care & Medicines Governance and Deputy Director of Pharmacy

Mr Keith Maclure – Prescribing Support Pharmacist

Dr Paul Neary – Consultant Cardiologist

Dr Nicola Henderson – GP

Amy Campbell – ST4 (representative for Junior Doctors)

Minute Secretary

Kate Warner – PA to Director of Pharmacy

3 Business

Core agenda items on the Committee's agenda include:-

- Committee members review New Medicine Applications for drugs from NHS Borders clinicians to be included in the formulary.
- Committee members note medicines reviewed by the Scottish Medicine Consortium (SMC), and guidance published by NICE, SIGN and NHS Quality Improvement Scotland (QIS).
- Borders Joint Formulary Updates – committee members review and approve changes to formulary sections. The committee supports development of guidelines & protocols relating to safe use of medicines.
- Patient Safety.
- For noting – minutes from Tissue Viability Group, Wound Formulary Group and NHS Lothian Formulary Committee; Single National Formulary updates.

4 BFC – Formulary, Guideline and Protocol Updates

FORMULARY UPDATES BROUGHT TO BFC MEETING – 10th APRIL 2019
Oralieve oral artificial saliva spray update; Diabetes, Obstetrics, Gynaecology, Urinary Tract formulary sections; Qutenza for pain formulary; Edoxaban and Testosterone formulary amendments.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 10th APRIL 2019
Cow's Milk Allergy; Alitretinoin; BFC Annual Report; Mercaptamine Eye Drops.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 12th JUNE 2019
Moved to August meeting.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 12th JUNE 2019
Non Formulary Request form update; Flowchart for Medicines Applications; Oralieve vs Salivase; Borders Abbreviated Formulary update.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 14th AUGUST 2019
Cardiology formulary section; topical Ibuprofen update; disease modifying anti-rheumatic drugs; sinusitis treatment formulary update.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 14th AUGUST 2019
Melatonin; Single National Formulary update.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 9th OCTOBER 2019
Gastroenterology – Imraldi and Zessly formulary updates;
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 9th OCTOBER 2019
Supply of Medicines for Cystic Fibrosis – Orkambi and Symkevi; Eskatamine; PPI Infson; Single National Formulary; Oxypro.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 11th DECEMBER 2019
Renal team formulary update; Dermatology biologics.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 11th DECEMBER 2019
Borders Abbreviated Formulary update; Vitamin D Guideline; Clopidrogel-Omeprazole interaction.
FORMULARY UPDATES BROUGHT TO BFC MEETING – 12th FEBRUARY 2020
Ivabradine; Catephen; Borders Joint Formulary Abbreviated update.
GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 12th FEBRUARY 2020
Electrolyte Deficiency Guideline update

5 BFC – Applications and Decisions

New Medicine Product/Device Endorsement Categories

A	Approved for general use - hospital and general practice
B	Approved for specialist use only
C	Approved for specialist initiation, with ongoing prescribing in general practice
D	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)
E	Not approved (reason given)
F	No decision – further information required (listed here)

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 10 th APRIL 2019			
NMA	Indication	Speciality	BFC Decision
Nintedanib (Ofev)	Treatment of idiopathic fibrosis (IPF)	Respiratory	Category B
Aviptadil / phentolamine (Invicorp)	For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or missed aetiology.	Urology	Category E
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 12 th JUNE 2019			
NMA	Indication	Speciality	BFC Decision
Semaglutide (Ozempic)	The treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in addition to other medicinal products for the treatment of diabetes. SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option	Diabetes	Category B
Zoledronic Acid	Osteoporosis	Rheumatology	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 14 th AUGUST 2019			
NMA	Indication	Speciality	BFC Decision
Mepolizumab	An add-on treatment for severe refractory eosinophilic asthma in adult patients.	Respiratory	Category B
Dalbavancin	On the advice of the Consultant Microbiologist for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults in patients with known MRSA or as a second line agent to allow patients to access IV therapy where deemed necessary and to prevent admission or reduce hospital length of stay where daily or three times a week therapy is not an option.	Microbiology	Category F
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 9 th OCTOBER 2019			
NMA	Indication	Speciality	BFC Decision
Buprenorphine (Espranor)	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine	Borders Addiction Service	Category B

	oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction for patients in whom methadone is not suitable.		
Buprenorphine (Buvidal)	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine prolonged release injection is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction for patients in whom methadone is not suitable.	Borders Addiction Service	Category B
Bevacizumab (Avastin)	Wet age-related macular degeneration.	Ophthalmology	Category F
Clozapine orodispersible (Zaponex)	Treatment resistant schizophrenia in patients who will not comply with normal release tablets.	Mental Health	Category B
Tildrakizumab (Ilumetri)	Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.	Dermatology	Category B
Micronised Progesterone (Utogestan)	Adjunctive use with oestrogen in post-menopausal women with an intact uterus (HRT)	Gynaecology	Category D
Denosumab (Xgeva)	Resistant Hypercalcaemia	Endocrine & Oncology	Category C
Plenvu	Adults for bowel cleansing prior to any procedure requiring a clean bowel.	Gastroenterology	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 11th DECEMBER 2019			
NMA	Indication	Speciality	BFC Decision
Zanamivir (Dectova)	For treatment of complicated and potentially life threatening influenza infection according to SMC advice.	Microbiology	Category B
Lusutrombopag (Mupleo)	Treatment of severe thrombocytopenia in patients with chronic liver disease undergoing invasive procedures.	Haematology	Category B
Aglomelatine	Major depressive disorder.	Mental Health	Category E
Escitalopram	Major depressive disorder.	Mental Health	Category E
Risankizumab (Skyrizi)	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Dermatology	Category B
Dolutegravir + Lamivudine (Dovato)	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.	Sexual Health	Category B
Ocrelizumab	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. SMC restriction: Treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for Alemtuzumab.	Neurology	Category B
Sodium bicarbonate simethicone and citric acid	Use distension of stomach in contrast Radiology.	Radiology	Category F

(Carbex)			
Nexus Voice Meter and Test strips (visually impaired patients); Contour Blood Glucose Meter and Strips (insulin pump patients); 4Sure Smart Duo Blood Glucose Meter and 4Sure Beta-ketone test strips (Type 1DM); 4Sure Smart Blood Glucose Meter and test strips (Type 2DM)		Diabetes	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 12th FEBRUARY 2020			
NMA	Indication	Speciality	BFC Decision
Medicinal Cannabis (Althea)	Pain	Pain	Category E
Dapagliflozin (Forxiga)	Treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI $\geq 27\text{kg/m}^2$, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy	Diabetes	Category C
Diveen (Diveen)	Urinary Incontinence	Bladder, Bowel & Pelvic Floor Service	Category B
Brivaracetam (Briviact)	Refractory seizures – focal onset with secondary generalisation.	Neurology	Category B

6 BFC Meeting Attendees 2019/20

Name	Meeting Dates					
	10.04.19	12.06.19	14.08.19	09.10.19	11.12.19	12.02.20
		Approved Virtually				
Mrs Alison Wilson	✓	-	✓	✓	✓	✓
Ms Liz Leitch	✓	✓	✓	✓	✓	✓
Mrs Catherine Scott	✓	-	No longer on committee			
Mrs Cathryn Park	-	-	-	✓	-	-
Mr Keith Maclure	✓	✓	✓	✓	✓	✓
Dr Paul Neary	✓	-	✓	✓	✓	✓
Dr Nicola Henderson	✓	-	✓	-	✓	✓
Amy Campbell	✓	-	✓	-	✓	-
Kate Warner (Minute)	✓	✓	✓		✓	✓
Guests						
Dr James Tidder				✓		
Adrian Mackenzie				✓		
Aleena Mehan				✓		
Emma Dodd					✓	
Fiona Hall					✓	
Maxine Angus					✓	
Dr Rob Forbes						✓
Abbie Gibson						✓

Declarations of Interest

No declarations of interest during 2019/20 meetings.